GHRP-2 GHRP-6 Hexarelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
These three — GHRP-2, GHRP-6, and Hexarelin — are first-generation “growth hormone releasing peptides”: short injectable molecules that hit the ghrelin receptor and trigger a natural GH pulse from your pituitary. Same target, three different side-effect profiles — GHRP-6 famously spikes hunger, GHRP-2 less so, and Hexarelin is the strongest but fades fastest with continued use.
Honest read: they work, but most people today choose the cleaner newer peptides (like Ipamorelin) for fewer off-target effects — these are the classics worth understanding.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The class profile is the GH-axis profile (mild flushing, water retention proportional to GH push, possible injection-site reactions, occasional headache) plus the off-target signature that distinguishes each compound:
| Compound | Class-shared | Distinguishing off-target |
|---|---|---|
| GHRP-2 | Mild water retention, flushing | Modest cortisol; mild appetite increase |
| GHRP-6 | Mild water retention, flushing | Intense hunger; stronger cortisol above saturation |
| Hexarelin | Mild water retention, flushing | Measurable cortisol + prolactin; 8-week desensitization ceiling |
Management defaults: start at the low end of the dose range, watch how your body responds for 1–2 weeks before escalating, cycle off as scheduled (don’t push past Hexarelin’s 8-week window), pull bloodwork if you’re running aggressive doses.
Hard contraindications: active malignancy or significant cancer-history concern (IGF-1 is a mitogen), active CHF or significant cardiac dysfunction (water-retention CV strain — the same physiology that ended MK-677 (Ibutamoren)'s elderly hip-fracture trial), uncontrolled diabetes (insulin-resistance signal compounds), pregnancy/breastfeeding, and any tested-athlete context (WADA-banned).
Regulatory status: None of the three are FDA-approved for any indication. All sit in the research-chemical / 503A gray zone. All three are WADA-prohibited and out-of-competition tested for in sport. The peptides themselves are sold internationally as “research compounds” — same regulatory tier as the other unapproved peptides in this wiki.
Part 1 — How to reconstitute it
What's used: bacteriostatic water (sterile, preserved water the powder is mixed with) and a separate, larger reconstitution syringe used only for mixing — not the small syringe used for administration.
Reconstitution math (universal across the three). A 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2,500 mcg/mL. On a U-100 insulin syringe (100 units = 1 mL):
- 100 mcg dose = 0.04 mL = 4 units
- 150 mcg dose = 0.06 mL = 6 units
- 200 mcg dose = 0.08 mL = 8 units
How it's mixed
- The vial is tilted and the bacteriostatic water is added slowly down the inside glass wall — not squirted straight onto the powder.
- It is swirled gently to dissolve. It is never shaken — shaking can damage the peptide.
- The reconstituted vial is stored refrigerated and out of light.
- Reconstituted peptides are commonly used within a few weeks, inside the beyond-use window the source specifies — that window varies by peptide.
The free reconstitution calculator does the concentration math for any vial size and water volume, including the equivalent units on an insulin syringe.
Part 2 — Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Administration as reported. Reported practice is subcutaneous administration (into the fat just under the skin) using a 0.3 mL U-100 insulin syringe, with sites rotated.
(If you have a 10 mg vial + 2 mL water = 5,000 mcg/mL: halve the units for the same mcg dose.)
GHRP-2 dosing
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100 mcg | Once daily before bed | Assess off-target tolerance |
| Intermediate | 150–200 mcg | 2× daily (fasted AM + bed) | Standard “more GH than Ipa” lane |
| Advanced | 200–300 mcg | 2–3× daily | Peak GH lever; cortisol/prolactin tracking advised |
Cycle: 8–12 weeks on / 4–8 weeks off. 5-on / 2-off micro-cycling within a block is the standard receptor-preservation move.
GHRP-6 dosing
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100 mcg | 1–2× daily | Hunger arrives within 20 min — plan meals around it |
| Intermediate | 100 mcg | 2–3× daily | Mass-building / hard-gainer lane |
| Advanced | 100–150 mcg | 3× daily | Saturation ceiling ~1 µg/kg — going higher gives more side effects, not more GH |
Cycle: 8–16 weeks on / 4–8 weeks off. The appetite effect persists through the cycle (it doesn’t desensitize the way the GH response does).
Hexarelin dosing
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Conservative | 50–100 mcg | 1–2× daily | Test desensitization tolerance |
| Standard | 100 mcg | 2–3× daily | Pre-workout / post-workout / pre-bed timing |
| Aggressive | 200 mcg | 2–3× daily | Bodybuilding lane; short cycles only |
Cycle: 4–8 weeks on / 4 weeks off: strict. The desensitization timeline doesn’t give you a choice. Baseline + mid-cycle bloodwork (prolactin, cortisol, IGF-1) is the standard for cycles longer than 6 weeks.
Timing (universal)
- Empty stomach — eating around the dose blunts the GH response.
- PM dosing rides the natural overnight GH pulse and is the default if dosing once daily.
- Pre-workout dosing is common for the workout-window GH-driven recovery effect.
What should I avoid combining — and what's synergistic?
Stacking — the GHRH side
All three pair with CJC-1295 for the dual-receptor synergy (same logic as CJC-1295 / Ipamorelin):
- CJC-1295 + GHRP-2 — the “max GH” stack for users for whom CJC + Ipa isn’t enough.
- CJC-1295 + Hexarelin — the “advanced potency + theoretical cardiac” stack; short cycles only.
- CJC-1295 + GHRP-6 — for hard-gainer / mass-building contexts where the appetite drive is the goal.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
The first-generation injectable GH secretagogues that hit the same ghrelin receptor as Ipamorelin and MK-677 (Ibutamoren) — but each carries its own off-target signature. The trade-off is potency vs cleanliness. Hexarelin is the strongest GH pulse in the class (and uniquely engages a cardiac receptor); GHRP-2 is the workhorse “more GH than Ipamorelin can give you” lever; GHRP-6 is the one whose ghrelin-driven hunger is so dominant it became the therapeutic mechanism for hard gainers. Ipamorelin won the daily-use war specifically by not doing what these three do at off-target sites — which is the cleanest cross-sell story in the GH-axis catalog.
| Field | GHRP-2 | GHRP-6 | Hexarelin |
|---|---|---|---|
| Class | Synthetic hexapeptide, GHS-R1a agonist | Synthetic hexapeptide, GHS-R1a agonist | Synthetic hexapeptide, GHS-R1a + CD36 agonist (dual receptor) |
| GH release magnitude | Strong: peak plasma GH 30–100 ng/mL (8–20× baseline) | Strong (similar to GHRP-2 at low doses; saturates ~1 µg/kg) | Strongest in class — 2–3× GH release of GHRP-2 / GHRP-6 / Ipamorelin at equivalent doses |
| Cortisol | Moderate (comparable to CRH at standard doses) | Stronger above the ~1 µg/kg saturation threshold | Measurable |
| Prolactin | Mild — lower than TRH-induced | Moderate at higher doses | Measurable |
| Appetite (hunger) | Increased but manageable | Dominant clinical effect: intense hunger 15–60 min post-dose | Moderate — overshadowed by potency and desensitization |
| Desensitization timeline | Slower: 8–12 week cycles common | Persists through cycle; 8–16 wk on / 4–8 wk off | Fastest in class — GH response drops ~week 8 |
| Best-fit use case | Maximum GH lever when Ipamorelin isn’t enough | Hard gainers, post-surgical, mass-building (hunger = therapeutic) | Maximum GH pulse + theoretical cardioprotection (short cycles only) |
| Regulatory | Research chemical; WADA-banned | Research chemical; WADA-banned | Research chemical; WADA-banned |
What they are
GHRP-2, GHRP-6, and Hexarelin are three synthetic hexapeptides (six amino acids each) developed across the 1980s–90s as the first generation of growth hormone releasing peptides — short, injectable molecules that hit the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and trigger a GH pulse. Same target, three different chemical scaffolds, three different off-target profiles.
This is the same receptor Ipamorelin hits (Ipamorelin is technically the fourth GHRP), and the same target MK-677 (Ibutamoren) hits orally. The receptor map is worth holding:
| Lane | Receptor | Members |
|---|---|---|
| GHRH side | GHRH-R | Sermorelin, CJC-1295, Tesamorelin |
| Ghrelin side, injectable | GHS-R1a | Ipamorelin, GHRP-2, GHRP-6, Hexarelin |
| Ghrelin side, oral | GHS-R1a | MK-677 (Ibutamoren) |
The reason CJC-1295 gets stacked with Ipamorelin (the CJC-1295 / Ipamorelin blend) is that the GHRH and ghrelin pathways trigger GH release through separate intracellular cascades in the same pituitary cells: hitting both simultaneously produces more GH than either alone, by roughly the synergy you’d predict. The same logic applies to stacking CJC-1295 with any of the three covered here: GHRP-2 + CJC, GHRP-6 + CJC, Hexarelin + CJC are all real protocols people run. They just bring the off-target effects along with the extra GH.
How they work (the shared mechanism)
All three bind GHS-R1a on pituitary somatotrophs → phospholipid-dependent signaling cascade → pulsatile GH release. Peak GH typically lands 30–45 minutes after a SubQ injection. Downstream: liver IGF-1 production → systemic IGF-1 elevation → the muscle/bone/recovery/sleep benefits the GH-axis catalog as a whole delivers.
Where they diverge is what else the GHS-R1a hit does, and (for Hexarelin) a second receptor in the picture.
The “potency vs cleanliness” trade-off is the central decision framework for this whole class. Ranking from cleanest profile to dirtiest:
Ipamorelin > GHRP-2 > GHRP-6 ≈ Hexarelin
Ipamorelin was specifically engineered for selective GHS-R1a binding — it triggers the GH-release branch of ghrelin signaling without meaningfully activating the cortisol, prolactin, or hunger branches that the other three do. That selectivity is the reason it became the daily-use default in the GH-axis world. The other three are stronger or have a specific use case, but they bring more off-target signaling along.
The foundational primary literature under this whole class:
- Arvat E et al. 1997: established that GHRP-2 and Hexarelin produced GH responses exceeding the maximal effective dose of GHRH in healthy adults. That’s the canonical study showing the ghrelin-side lever is at least as strong as the GHRH-side lever.
- Laferrere B et al. 2005: established GHRP-2’s appetite-increasing effect cleanly in humans.
GHRP-2 — the strong, workhorse GH lever
Mechanism: Synthetic hexapeptide; binds GHS-R1a in pituitary + hypothalamus.
GH release: Strong — peak plasma GH 30–100 ng/mL within 15–30 minutes (8–20× baseline, depending on dose and individual response). Exceeds the maximum effective dose of GHRH alone on its own.
Off-target profile:
- Cortisol: Moderate — comparable to CRH at standard doses.
- Prolactin: Mild — lower than TRH-induced elevation.
- Appetite: Increased but manageable — not the dominant clinical effect, unlike GHRP-6.
Best use case: GH-axis users who need more potency than Ipamorelin can deliver and are willing to accept mild off-target signaling to get it. Common in advanced GH-stack protocols.
GHRP-6 — the ghrelin-driven hunger peptide
Mechanism: Synthetic hexapeptide; binds GHS-R1a. Carries the full behavioral and hormonal baggage of ghrelin-receptor agonism — including the appetite signal at its strongest.
GH release: Strong at low doses (similar to GHRP-2), but saturates above roughly 1 µg/kg — pushing the dose past saturation gives you more side effects, not more GH.
Off-target profile:
- Hunger: The strongest of any GHRP. Users report intense hunger within 15–20 minutes of injection, lasting 30–60 minutes. This is the dominant clinical effect — most people stop on dose-discovery noticing the hunger before anything else.
- Cortisol: Stronger than GHRP-2, especially above the ~1 µg/kg saturation threshold.
- Prolactin: Moderate at higher doses.
The therapeutic reframe (important). GHRP-6’s hunger effect is usually described as a side effect: but for a specific clinical context, it is the therapeutic mechanism:
- Hard gainers who can’t eat enough to support muscle growth on training.
- Post-surgical recovery patients with nutritional intake problems.
- Mass-building phases where appetite is the rate-limiting factor.
In those contexts, the intense hunger is exactly what you’re paying for. For literally any other use case, GHRP-2 or Ipamorelin is the better-engineered answer.
Hexarelin — the strongest GH pulse + the cardiac wildcard
Mechanism: Synthetic hexapeptide; dual-receptor activity — uniquely:
- GHS-R1a in pituitary + hypothalamus — like all GHRPs, drives the GH pulse.
- CD36 receptor on cardiac tissue — absent in Ipamorelin and GHRP-2. This is Hexarelin’s most distinctive pharmacological feature.
GH release: The strongest in the class: 2–3× the GH release of Ipamorelin / GHRP-2 / GHRP-6 at equivalent doses. Peak GH release at 30–45 minutes post-injection.
Off-target profile:
-
Cortisol: Measurable.
-
Prolactin: Significant — this is a disqualifying liability for most use cases. Prolactin is the same hormone released post-ejaculation; elevated prolactin creates persistent fatigue, reduced libido, and hormonal disruption that undercuts the purpose of running a GH peptide in the first place. For male users on any quality-of-life or performance protocol, prolactin elevation from hexarelin is the primary reason to prefer Ipamorelin instead.
-
Appetite: Significant increase. Makes hexarelin counterproductive for fat-loss or cut phases; only useful if the appetite signal is the therapeutic target (bulking / hard-gainer).
-
Desensitization: Fastest of any GHRP — and this is the origin of the cycling protocol for ALL ghrelin agonists, including Ipamorelin. Specific data from a cited study: after 8 weeks of daily hexarelin administration, IGF-1 response dropped by approximately 45% due to GHS-R1a desensitization on the pituitary. After 4 weeks off, IGF-1 returned to baseline.
The Ipamorelin cycling rationale derives from this data: no direct study has measured ipamorelin’s desensitization rate at its typical doses. The convention to cycle ipamorelin is extrapolated from the hexarelin desensitization study — hexarelin sets the worst-case bound (it will desensitize; therefore all GHS-R1a agonists are cycled as precaution). This is why the hexarelin data belongs in every GHRP wiki: it’s the scientific bedrock for the cycling recommendation that applies across the whole class.
The cardiac angle: worth knowing, worth verifying carefully. The CD36 receptor on cardiac tissue is the proposed mechanism for Hexarelin’s preclinical cardioprotective effects — improvements in ischemia/reperfusion models, post-MI cardiac function. This is theoretically interesting and could position Hexarelin as a member of a cardiac-protection stack alongside MOTS-c and TB-500 (both with their own cardiac data). The human translation of the CD36 work is not yet established and the safety profile of Hexarelin for chronic cardiac use is unstudied — so this stays in the “interesting class-distinguishing pharmacology” file, not the “established cardioprotective therapy” file.
Best use case: Maximum GH pulse for short, high-intensity cycles. Bodybuilding-style use where the 4–8 week ceiling fits the periodization. Worst case: any attempt at long-term continuous use — the molecule defeats itself.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Reconstitution math (universal across the three). A 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2,500 mcg/mL. On a U-100 insulin syringe (100 units = 1 mL):
- 100 mcg dose = 0.04 mL = 4 units
- 150 mcg dose = 0.06 mL = 6 units
- 200 mcg dose = 0.08 mL = 8 units
(If you have a 10 mg vial + 2 mL water = 5,000 mcg/mL: halve the units for the same mcg dose.)
GHRP-2 dosing
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100 mcg | Once daily before bed | Assess off-target tolerance |
| Intermediate | 150–200 mcg | 2× daily (fasted AM + bed) | Standard “more GH than Ipa” lane |
| Advanced | 200–300 mcg | 2–3× daily | Peak GH lever; cortisol/prolactin tracking advised |
Cycle: 8–12 weeks on / 4–8 weeks off. 5-on / 2-off micro-cycling within a block is the standard receptor-preservation move.
GHRP-6 dosing
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100 mcg | 1–2× daily | Hunger arrives within 20 min — plan meals around it |
| Intermediate | 100 mcg | 2–3× daily | Mass-building / hard-gainer lane |
| Advanced | 100–150 mcg | 3× daily | Saturation ceiling ~1 µg/kg — going higher gives more side effects, not more GH |
Cycle: 8–16 weeks on / 4–8 weeks off. The appetite effect persists through the cycle (it doesn’t desensitize the way the GH response does).
Hexarelin dosing
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Conservative | 50–100 mcg | 1–2× daily | Test desensitization tolerance |
| Standard | 100 mcg | 2–3× daily | Pre-workout / post-workout / pre-bed timing |
| Aggressive | 200 mcg | 2–3× daily | Bodybuilding lane; short cycles only |
Cycle: 4–8 weeks on / 4 weeks off: strict. The desensitization timeline doesn’t give you a choice. Baseline + mid-cycle bloodwork (prolactin, cortisol, IGF-1) is the standard for cycles longer than 6 weeks.
Timing (universal)
- Empty stomach — eating around the dose blunts the GH response.
- PM dosing rides the natural overnight GH pulse and is the default if dosing once daily.
- Pre-workout dosing is common for the workout-window GH-driven recovery effect.
Stacking — the GHRH side
All three pair with CJC-1295 for the dual-receptor synergy (same logic as CJC-1295 / Ipamorelin):
- CJC-1295 + GHRP-2 — the “max GH” stack for users for whom CJC + Ipa isn’t enough.
- CJC-1295 + Hexarelin — the “advanced potency + theoretical cardiac” stack; short cycles only.
- CJC-1295 + GHRP-6 — for hard-gainer / mass-building contexts where the appetite drive is the goal.
Side effects & management
The class profile is the GH-axis profile (mild flushing, water retention proportional to GH push, possible injection-site reactions, occasional headache) plus the off-target signature that distinguishes each compound:
| Compound | Class-shared | Distinguishing off-target |
|---|---|---|
| GHRP-2 | Mild water retention, flushing | Modest cortisol; mild appetite increase |
| GHRP-6 | Mild water retention, flushing | Intense hunger; stronger cortisol above saturation |
| Hexarelin | Mild water retention, flushing | Measurable cortisol + prolactin; 8-week desensitization ceiling |
Management defaults: start at the low end of the dose range, watch how your body responds for 1–2 weeks before escalating, cycle off as scheduled (don’t push past Hexarelin’s 8-week window), pull bloodwork if you’re running aggressive doses.
Hard contraindications: active malignancy or significant cancer-history concern (IGF-1 is a mitogen), active CHF or significant cardiac dysfunction (water-retention CV strain — the same physiology that ended MK-677 (Ibutamoren)'s elderly hip-fracture trial), uncontrolled diabetes (insulin-resistance signal compounds), pregnancy/breastfeeding, and any tested-athlete context (WADA-banned).
Regulatory status
None of the three are FDA-approved for any indication. All sit in the research-chemical / 503A gray zone. All three are WADA-prohibited and out-of-competition tested for in sport. The peptides themselves are sold internationally as “research compounds” — same regulatory tier as the other unapproved peptides in this wiki.
Technical & analytical reference (chemistry & QC)
Verified identity values (PubChem / CAS; identity confirmed, not from the analytical capture):
| Peptide | Formula | Avg MW | CAS | Sequence | PubChem CID |
|---|---|---|---|---|---|
| GHRP-2 | C45H55N9O6 | 817.97 | 158861-67-7 | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 | 9831663 |
| GHRP-6 | C46H56N12O6 | 873.01 (monoisotopic 872.44) | 87616-84-0 | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | 4345065 |
| Hexarelin | C47H58N12O6 | 887.04 | 140703-51-1 | His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 | — |
Notable analytical / QC detail (per peptide):
- GHRP-6 — the two MW figures sometimes seen for this peptide are not a contradiction: 873.01 is the average molecular weight, 872.44 is the monoisotopic mass.
- Hexarelin — the D-2-methyl-Trp residue is the distinguishing structural feature vs the other two hexapeptides; confirm by LC-MS against the 887.04 average mass.
- GHRP-2 / GHRP-6 / Hexarelin — all three are synthesized as the acetate or TFA salt; standard identity QC = HPLC-UV purity + LC-MS mass confirmation against the average MW above.
Citation leads (PeptideBiologix; until confirmed): PeptideBiologix analytical pages for GHRP-2, GHRP-6, and Hexarelin (raw captures, ghrp-6.md, hexarelin.md) — method/PK detail only; identity values above are from PubChem/CAS, not the captures.
Sources
- Arvat E, et al. GHRP-2 and Hexarelin exceed max GHRH-induced GH release in humans. J Clin Endocrinol Metab 1997.
- Laferrere B, et al. Growth-hormone-releasing peptide-2 increases food intake in humans.
- Hexarelin CD36 cardiac receptor mechanism and preclinical cardioprotective data.
- Research note — GHRP-2 vs GHRP-6 vs Hexarelin (text aggregation: mechanism, off-target profiles, dose protocols, cycle structures, desensitization timelines).
- One practitioner T. CJC-1295 / Ipamorelin Masterclass — Ipamorelin selectivity vs GHRP-2/6 framing.
- Holyfield. CJC-1295 / Ipamorelin mechanism + timeline — Ipa “no cortisol/prolactin/hunger” framing.
- Holyfield. “I Only Take 2 Peptides — Here’s Why | Weekly Q&A” — hexarelin 45% IGF-1 drop at 8 weeks, 4-week recovery, prolactin elevation characterization, appetite issue, narrow use case. This is the most specific desensitization data added to the KB for this compound.
- peptidedeck.com — Hexarelin peptide reference. https://www.peptidedeck.com/peptides/hexarelin-peptide
- peptidepedia.org — GHRP-2 vs GHRP-6 guide. https://peptidepedia.org/guides/ghrp-2-vs-ghrp-6
See also: Ipamorelin, CJC-1295, CJC-1295 / Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren), MOTS-c, TB-500.
Sources & references
- Arvat E, et al. GHRP-2 and Hexarelin exceed max GHRH-induced GH release in humans. J Clin Endocrinol Metab 1997.
- Laferrere B, et al. Growth-hormone-releasing peptide-2 increases food intake in humans.
- Hexarelin CD36 cardiac receptor mechanism and preclinical cardioprotective data.
- Research note — GHRP-2 vs GHRP-6 vs Hexarelin (text aggregation: mechanism, off-target profiles, dose protocols, cycle structures, desensitization timelines).
- One practitioner T. CJC-1295 / Ipamorelin Masterclass — Ipamorelin selectivity vs GHRP-2/6 framing.
- Holyfield. CJC-1295 / Ipamorelin mechanism + timeline — Ipa “no cortisol/prolactin/hunger” framing.
- Holyfield. “I Only Take 2 Peptides — Here’s Why | Weekly Q&A” — hexarelin 45% IGF-1 drop at 8 weeks, 4-week recovery, prolactin elevation characterization, appetite issue, narrow use case. This is the most specific desensitization data added to the KB for this compound.
- peptidedeck.com — Hexarelin peptide reference. https://www.peptidedeck.com/peptides/hexarelin-peptide
- peptidepedia.org — GHRP-2 vs GHRP-6 guide. https://peptidepedia.org/guides/ghrp-2-vs-ghrp-6
See also: Ipamorelin, CJC-1295, CJC-1295 / Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren), MOTS-c, TB-500.